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Background:  We  aimed  to  evaluate  clinical  symptoms  in  subjects  with  irritable  bowel  syndrome  receiving
Saccharomyces  cerevisiae  in  a randomized  double-blind  placebo-controlled  clinical  trial.
Methods: Overall,  179  adults  with  irritable  bowel  syndrome  (Rome  III  criteria)  were  randomized  to  receive
once  daily  500 mg of Saccharomyces  cerevisiae,  delivered  by one  capsule  (n = 86,  F:  84%,  age:  42.5  ±  12.5),  or
placebo  (n  = 93, F:  88%,  age:  45.4  ±  14)  for  8  weeks  followed  by a 3-week  washout  period.  After  a  2-week
run-in  period,  cardinal  symptoms  (abdominal  pain/discomfort,  bloating/distension,  bowel  movement
difﬁculty)  and changes  in stool  frequency  and  consistency  were  recorded  daily and  assessed  each  week.
A  safety  assessment  was  carried  out  throughout  the study.
Results: The  proportion  of responders,  deﬁned  by  an improvement  of abdominal  pain/discomfort,  was
signiﬁcantly  higher  (p =  0.04)  in the  treated  group  than  the placebo  group  (63%  vs  47%, OR  =  1.88, 95%,
CI:  0.99–3.57)  in  the  last  4 weeks  of  treatment.  A non-signiﬁcant  trend  of improvement  was  observed
with  Saccharomyces  cerevisiae  for the other  symptoms.  Saccharomyces  cerevisiae  was  well  tolerated  and
did  not  affect  stool  frequency  and  consistency.
Conclusion: Saccharomyces  cerevisiae  is  well  tolerated  and  reduces  abdominal  pain/discomfort  scores
without  stool  modiﬁcation.  Thus,  Saccharomyces  cerevisiae  may  be a new  promising  candidate  for  improv-
ing  abdominal  pain  in  subjects  with irritable  bowel  syndrome.
©  2014  Editrice  Gastroenterologica  Italiana  S.r.l.  Published  by Elsevier  Ltd.  
D lice. Introduction
Irritable bowel syndrome (IBS) is a common functional gastroin-
estinal disorder with a worldwide prevalence of 5–15%, accounting
or 3% of the visits to general practitioners and about 40% of all gas-
roenterology outpatient consultations [1]. This high prevalence is
ssociated with annual direct and indirect costs of more than 20
Open access under CC BY-NC-Nillion USD/year in the USA, corresponding to 3.5 million physician
isits annually, and is one of the leading causes of work absenteeism
2,3]. Despite the prevalence and impact of IBS in the community,
∗ Corresponding author at: Service des maladies de l’appareil digestif et de la
utrition, Hôpital Claude Huriez, CHRU 59800 Lille, France. Tel.: +33 320444714;
ax:  +33 320444713.
E-mail address: pdesreumaux@hotmail.com (P. Desreumaux).
ttp://dx.doi.org/10.1016/j.dld.2014.11.007
590-8658/© 2014 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. Opits pathogenesis remains unclear, and the efﬁcacy of treatments
using pharmacological and probiotic approaches is modest, focus-
ing mainly on abdominal pain and bloating, considered as the two
dominant and most troublesome symptoms of IBS [4].
IBS  pathogenesis is multifactorial and involving at least visceral
hypersensitivity, gastrointestinal motor dysfunction, dysregulation
of the brain–gut axis, psychosocial, genetic, and environmental fac-
tors, as well as low grade intestinal inﬂammation [5]. The possibility
that gut microbiota may  have a role in IBS is supported by descrip-
tive culture- and molecular-based studies in patients showing the
following characteristics: a temporal instability and a reduction of
the diversity of the enteric microbial populations, excessive bacte-
nse.ria in the small bowel, decreased levels of colonic lactobacilli and
biﬁdobacteria, increased numbers of strict and facultative anaero-
bic organisms, and increased ratios of luminal dominant Firmicutes
compared to Bacteroidetes phylas [6]. In addition, evidences of
en access under CC BY-NC-ND license.
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etabolic activity alteration of the intestinal ﬂora [7], together with
bservations that post-acute enteric infection leading to IBS-like
yndrome accounts for 25% of the overall IBS population [8], rein-
orce a potential role for the gut microbiota in some patients with
BS. Based on these data, the beneﬁts of microbiota-directed ther-
pies have been evaluated in IBS using antibiotics, diets containing
ow fermentable saccharides and polyols, prebiotics, and probiotics
9]. Probiotics are live microorganisms that, when given in sufﬁ-
ient amount, confer a health beneﬁt to the host [10]. Probiotics
an be bacteria, virus, parasites, or yeasts. The main clinical fea-
ure of IBS is abdominal discomfort and/or abdominal pain. In these
BS patients, a recent systematic review of randomized controlled
rials indicates that probiotics, mainly belonging to the genus Lac-
obacillus and/or Biﬁdobacterium, have a trend for being efﬁcacious;
owever, the magnitude of beneﬁt and the mechanisms of actions
f these strains are still unknown [11].
In a previous study, it has been shown that a speciﬁc strain of
actobacillus acidophilus, NCFM, was able to decrease the visceral
ain perception in rats via induction of the Mu  opioid receptor and
annabinoid receptor expression by colonic epithelial cells [12].
ore recently, we reported that a new strain of Saccharomyces
erevisiae, CNCM I-3856, selected from the Lesaffre baker’s yeast
train collection, had analgesic effects in the gut through a local
ctivation of the peroxisome proliferator-activated receptor alpha
12]. In this preclinical study, oral administration of CNCM I-3856
mproved pain similarly to the standard dosage of morphine in
 model of colorectal distension in rats. This analgesic effect was
ose-dependent with a maximal effect at 1010 CFU/day, corre-
ponding to the classical active dose of probiotics used in most
uman clinical trials [11]; the effect appeared 15 days after the
eginning of probiotic administration and was transitory, disap-
earing 3 days after the last CNCM I-3856 administration.
Given this preclinical evidence of the analgesic effect of CNCM
-3856 in the gut, the aim of this study was to investigate whether
ral administration of CNCM I-3856 is effective in alleviating IBS
ymptoms in a randomized double-blind placebo-controlled clini-
al trial.
.  Materials and methods
.1.  Patients
Patients were recruited in one investigative site at Biofortis, in
antes, France. Patients included were males and females between
8 and 75 years of age with a diagnosis of IBS according to the
ome III criteria [14] and a pain/discomfort score strictly above
 and strictly below 6, as determined on a pain/discomfort scale
sing arbitrary grading from 0 to 7 in the 7 days preceding the
nclusion visit (Fig. 1). Subjects had normal blood counts, within
eference values, for serum creatinine, urea, alkaline phosphatase,
otal bilirubin, gamma-glutamyl transferase (GT), liver transami-
ases (ALT, ALP), and thyroid-stimulating hormone (TSH), and had
-reactive protein (CRP) levels below twice the upper limit of the
ormal value of the laboratory. Treatments for diarrhoea, laxatives,
nd antispasmodic drugs were not exclusion criteria under the
ondition that they had been started more than 1 month before
ig. 1. Study design. A 13-week study including a run-in, treatment and follow-up
eriods  with ﬁve medical visits.nd Liver Disease 47 (2015) 119–124
inclusion without dose modiﬁcation until the end of the study.
Hormone treatment in menopausal women, or contraception in
non-menopausal women  must have been started at least 3 months
beforehand at stable doses and without modiﬁcation for the entire
duration of the study.
Subjects  were excluded if they had organic intestinal diseases,
underwent treatments likely to inﬂuence IBS, in particular by mod-
ifying intestinal sensitivity or motility (antidepressants, opioids,
and narcotic analgesics), had antibiotic therapy in progress or
prescribed in the 8 weeks before inclusion in the study, or had long-
term treatment with analgesics or non-steroidal anti-inﬂammatory
drugs. Subjects not willing to stop taking probiotics, prebiotics,
or synbiotics in the form of dietary supplements or convenience
goods were not eligible. Pregnancy in progress, chronic alcoholism,
vegetarian or vegan regimens, eating disorders such as anorexia
or bulimia, and documented food allergies were all exclusion
criteria.
2.2. Study design
This  was a 13-week single-centre double-blind placebo-
controlled clinical study randomizing 2 parallel groups of 100 IBS
patients. During a 2-week run-in period, scores for abdominal
pain/discomfort (deﬁned as an uncomfortable sensation corre-
sponding to a continuum between discomfort and pain), bloating
and ﬂatulence, difﬁculty with defecation, stool frequency, and con-
sistency were recorded (Fig. 1). Dietary recommendations were
explained to each patient in particular concerning the consumption
of fermented dairy products and certain cheeses. After veriﬁca-
tion of the inclusion/exclusion criteria, eligible IBS patients were
randomized to consume daily, for 8 weeks, either 1 capsule of
S. cerevisiae CNCM I-3856 (500 mg,  8 × 109 CFU/g) or a placebo
(calcium phosphate). A total of ﬁve medical visits were regularly
scheduled during the 13-week study, including the 3 weeks of
follow-up (Fig. 1). The study was  conducted in accordance with
the Declaration of Helsinki and its protocol was approved by the
Ethics Committee of Amiens, France. All subjects provided written
informed consent before inclusion in the study.
2.3. Study products and compliance evaluation
The products studied were presented in capsule form and pack-
aged in blister packs of 15. All capsules of active product and
placebo were without ﬂavour and had the same size, colour, and
vegetal hydroxypropylmethylcellulose composition. They were to
be taken orally, one capsule a day, in the morning at breakfast time
with a glass of water. The probiotic preparation speciﬁcally con-
tained 500 mg  per capsule of S. cerevisiae CNCM I-3856 (8 × 109
CFU/g). The placebo consisted of a 500 mg  dibasic calcium phos-
phate.
The CNCM I-3856 strain is a proprietary, well-characterized
strain of Lesaffre. The S. cerevisiae species were characterized by
using both phenotypic (API® ID32C, Biomerieux SAS) and genotypic
referenced methods (genetic ampliﬁcation and sequencing of 26S
DNA) [15,16]. Moreover, the strain CNCM I-3856 was  identiﬁed by
PCR Interdelta typing technique and complete genome sequencing
[17].
Patients had to return all their treatment units, whether con-
sumed or not, to calculate compliance, which was  evaluated during
the treatment period at visits V2 and V3.
2.4. Assessment of symptoms and study endpointsThe primary endpoint speciﬁed in the protocol was the evo-
lution of abdominal pain/discomfort evaluated daily and assessed
each week during the 13-week study according to a 7-point Likert
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(+0.31 ± 0.02, p = 0.012: Fig. 3, Table 2). The effect of the product on
abdominal pain/discomfort scores was  similar whatever the type
of subjects (IBS-C, IBS-D, or IBS-M) and in the ITT population, with
Table 1
Baseline characteristics of the 179 subjects: comparison between groups.
Placebo group
n  (%)
Product group
n  (%)
P value
n 93 86
Female 82 (88%) 72 (84%) 0.51
Age 45.4 ± 14 42.5 ± 12.5 0.85
Smoker 18 (20%) 26 (30%) 0.12
IBS-C 43 (46%) 41 (48%) 0.88
IBS-D 27 (29%) 24 (28%) 0.88
IBS-M 23 (25%) 21 (24%) 1
Pain/discomforta,b 3.16 ± 1.1 3.22 ± 1.12 0.76
Bloating scorea,b 3.26 ± 1.31 3.46 ± 1.23 0.39
Bowel movement difﬁcultya,b 2.56 ± 1.6 2.61 ± 1.72 0.94
Stool frequencya,c 1.2 ± 0.65 1.21 ± 0.67 0.78
a,cG. Pineton de Chambrun et al. / Diges
cale [18]. Abdominal pain/discomfort scores were ﬁrst analyzed
sing the area under the curve (AUC) in placebo and treatment
roups, where the score at week 0 (W0), deﬁned as a baseline
alue, was added to the model to improve adjustment. A second
nalysis comparing the percentage of subjects who  experienced
n improvement in their abdominal pain/discomfort in the last 4
eeks of the treatment period was carried out using the Cochran-
antel-Haenszel test. Improvement was deﬁned as a reduction in
he abdominal pain/discomfort score of 1 arbitrary unit (au) for at
east 50% of the time, i.e. for at least 2 weeks out of 4 [19].
Secondary outcome measures were the weekly scores of bloat-
ng/distension and bowel movement difﬁculty, recorded daily in
he same condition using the 7-point Likert scales [18]. Changes
n stool frequency and consistency were followed daily using the
ristol Stool Scale (ranging from 1, corresponding to separate hard
umps, to 7 for entirely liquid stools) [20].
.5. Safety variables
Adverse  events were recorded by patients and immediately
ransmitted to the investigator to estimate their severity. Severe
nd non-severe adverse events were recorded on two  different
orms. The list of severe adverse events was transmitted to the
uthorities every six months throughout the study.
.6.  Sample size
On  the basis of preclinical data obtained in a model of rectal dis-
ension in rats receiving S. cerevisiae CNCM I-3856 [13], a reduction
f 20% or 25% in the abdominal pain/discomfort score was assumed.
ith a power of 80% and a signiﬁcance level of 0.05, the difference
etween the treatment versus placebo groups would be statistically
igniﬁcant with 106 and 66 patients, respectively. In the present
tudy, inclusion of 100 patients per group was considered realistic.
.7. Randomization and statistical methods
Randomization and statistical analyses were conducted using
AS software version 9.1.3 (SAS Institute Inc., Cary, NC, USA). Each
ubject included at the visit (V1) received in a random manner
ne of the two products (placebo or active). Block randomization
as performed by type of subject (with predominant constipation
IBS-C), with predominant diarrhoea (IBS-D), or mixed symptoms
IBS-M)) with dynamic allocation software using the block permu-
ation technique. Product allocation remained blind throughout the
tudy.
The AUCs (W1-W8) of the abdominal pain/discomfort scores,
loating/distension scores, and bowel movement difﬁculty scores
as calculated and analyzed using an ANCOVA model including
erms of treatment, type of bowel habit (diarrhoea, constipation, or
ixed), treatment/type interaction, and baseline value of the score
t W0  as a covariate in the statistical model. Analysis of these scores
as performed at each week of the treatment period using the same
NCOVA model. For all score outcomes, intra-group analyses were
onducted using the paired Student’s t-test to compare baseline
alues to each week of the treatment period.
The number of adverse events and their severity were compared
etween the treatment and placebo groups (with Fisher’s exact test
nd chi-square test).
The  analysis of efﬁcacy was performed on the per-protocol
PP) population as well as on the Intention-To-Treat (ITT) popu-
ation. This study presents the PP and ITT analysis results taking
nto account the included subjects ﬁnishing the study without any
ajor protocol violation.nd Liver Disease 47 (2015) 119–124 121
3. Results
3.1. Patients
Baseline characteristics of the patients in the placebo and treat-
ment groups showed no signiﬁcant differences (Table 1). The ﬂow
of subjects through the protocol is presented in Fig. 2. From the 262
screened subjects, 200 were randomized and equally distributed
between the placebo (n = 100) and treatment (n = 100) groups. Six
subjects were rapidly excluded (1 with systemic disease, 5 volun-
tary withdrawals) and 15 discontinued the intervention (antibiotic
treatment (n = 12), bladder tumour (n = 1), antidepressant treat-
ment (n = 1), colorectal cancer (n = 1) leaving 86 and 93 subjects
assigned to the treatment and placebo groups, respectively, and
giving an ITT population of 179. A majority of patients (46.9%) were
IBS-C subjects (46.2% and 47.7% in the placebo and product groups,
respectively). Good compliances were recorded in both the pro-
biotic and placebo groups for the ﬁrst and the second month of
administration (respectively for V2 + V3 99% ± 2.7 and 99% ± 3.2:
Table 1).
3.2.  Primary outcome measures
Abdominal pain/discomfort scores, expressed in au on a scale
from 0 (no symptoms) to 7 (severe symptoms), showed homo-
geneity at baseline for both the placebo (3.16 ± 1.1) and product
(3.22 ± 1.12) groups (p = 0.76). Intragroup analysis revealed a sig-
niﬁcant reduction of the score both in the probiotic and placebo
groups throughout the 8 weeks of treatment period (W0–8);
this led to a mean score reduction of 26.9% and 37.2% com-
pared with baseline, respectively in the placebo and product group
(p < 0.001 in both treated groups; Fig. 3, Table 2). This inter-
group difference for abdominal pain/discomfort AUC  during the 8
weeks of treatment was not signiﬁcant (p = 0.13). The reduction
of abdominal pain/discomfort scores was  higher during the ﬁrst
month than the second month of placebo administration (2.42 ± 1.5
vs 0.11 ± 1.49). During the period of follow-up without product
administration (W8–11), the abdominal pain/discomfort score did
not vary signiﬁcantly in the placebo group (p = 0.89) but contin-
ued to decrease (−0.02 ± 0.07). In contrast, this score showed a
signiﬁcant increase between W8  and W11  in the product groupStool consistency 3.39 ± 1.19 3.52 ± 1.24 0.24
Compliancea 99± 2.7% 99± 3.2% >0.9
IBS-C, constipation predominant IBS; IBS-D, diarrhoea predominant IBS; IBS-M,
mixed IBS.
a Mean ± SD.
b Assessed with a 7-point Likert scale.
c assessed using the Bristol Stool scale.
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Fig. 2. Flowchart of the patie
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Sig. 3. Evolution of abdominal pain/discomfort scores (7-point Likert scale,
ean  ± SEM) in placebo and product groups through the study.
able 2
volution of abdominal pain/discomfort scores (7-point Likert Scale) during the study in 
Placebo group
>Mean  ± SD
P value intragrou
Week 0 3.16 ± 1.1 
Week  8 2.31 ± 1.49 
Week  11 2.29 ± 1.56 
Change  between baseline versus
end of treatment period
−0.85  ± 1.44
(−27%)
<0.0001 
Change  between end of treatment
period versus follow up period
−0.02  ± 0.07 0.89 
D, standard deviation.nts through the study.
regard to the non-signiﬁcant treatment/type interaction in the sta-
tistical models (data not shown).
Analysis of improvement in abdominal pain/discomfort demon-
strated a signiﬁcantly higher percentage of subjects experiencing
improvement in the product group than the placebo group dur-
ing the second month of S. cerevisiae administration (respectively
62.8% vs 47.3%, p = 0.04).
3.3. Secondary outcome measures
Scores evaluating bloating/distension, bowel movement difﬁ-
culty, stool frequency, and stool consistency showed homogeneity
at baseline for both the placebo and product groups (Table 1).
Intragroup analysis revealed a signiﬁcant reduction of bloat-
ing/distension and bowel movement difﬁculty scores compared
with baseline both in the product and placebo groups throughout
the 8-week treatment period (W0–W8) (p < 0.001 in both treated
groups), but without intergroup differences. Stool frequency and
stool consistency scores remained similar during the 8 weeks
of treatment without intragroup and intergroup differences. The
placebo and product groups.
p Product
groupMean ± SD
P value intragroup P value intergroup
3.22 ± 1.12 0.76
2.03 ± 1.122 0.13
2.34 ± 1.24 0.98
−1.2 ± 1.31
(−37%)
<0.0001 0.09
+0.31 ± 0.02 0.012 0.98
tive a
e
(
n
(
3
e
a
o
c
r
7
d
f
g
p
g
p
(
(
(
i
p
d
4
d
3
i
i
o
o
S
p
t
i
t
a
r
B
p
I
S
T
p
a
b
r
s
T
p
p
o
b
n
p
i
iG. Pineton de Chambrun et al. / Diges
ffect of the product was similar whatever the type of subjects
IBS-C, IBS-D, or IBS-M) and in the ITT population, with regard to the
on-signiﬁcant treatment/type interaction in the statistical models
data not shown).
.4.  Adverse events
No  signiﬁcant adverse event was recorded during the study in
ither the placebo or product group. The frequency of subjects with
t least one adverse event was similar in the two  groups through-
ut the study (50.35% vs 49.65%, p = 0.88). Sixty-ﬁve adverse events
onsidered to have a potential connection with the study were
eported. The most frequent symptoms, representing more than
0% of these adverse events, were abdominal pain/bloating (n = 15),
iarrhoea (n = 14), constipation (n = 13), and headache (n = 6). Their
requencies were similar in the placebo (n = 31) and product (n = 34)
roups (p = 0.94).
Two subjects reported a serious adverse event: a bladder neo-
lasm in the product group and a colorectal cancer in the placebo
roup. Fourteen signiﬁcant adverse events were recorded in the
lacebo (n = 9) and product (n = 5) groups: abdominal pain/bloating
n = 5), dorsal pain (n = 2), gastroesophageal reﬂux (n = 2), diarrhoea
n = 1), headache (n = 1), urinary infection (n = 1), ﬂu-like syndrome
n = 1), and haemorrhoidal crisis (n = 1). There was  no difference
n severity between the events in the active product group and the
lacebo group (p = 0.28). Finally, no change in blood parameters was
etected throughout the study in the placebo and product groups.
.  Discussion
The present randomized double-blind placebo-controlled study
emonstrates, in a French population, that S. cerevisiae CNCM I-
856 is a safe yeast strain able to relieve abdominal pain/discomfort
n IBS patients fulﬁlling the Rome III criteria. This 13-week clin-
cal trial was performed according to the recommended designs
f treatment trials for functional gastrointestinal disorders [4], in
rder to demonstrate statistical superiority of a treatment with
. cerevisiae for the most invalidating symptom characterizing IBS
atients.
This is the ﬁrst clinical trial reporting a statistical efﬁcacy of yeast
reatment on abdominal pain/discomfort in IBS patients. Abdom-
nal pain/discomfort was chosen as the primary end point since
he selected strain of S. cerevisiae CNCM I-3856 was able to induce
 strong visceral analgesic effect allowing a 50% increased colo-
ectal distension threshold in treated versus untreated rats [13].
ased on these data, and expecting a 20% therapeutic gain over
lacebo for the score assessing abdominal pain/discomfort, 200
BS patients were randomized and treated for 8 weeks with either
. cerevisiae CNCM I-3856 at a daily dose of 500 mg,  or placebo.
he 2-week prospective baseline observation period ensured that
atients were currently symptomatic, with a comparable moder-
te abdominal pain score of 3.2 on the seven-point Likert scale, in
oth the active and placebo groups [20]. Even if the optimal dose
emains to be clearly established, the daily intake of 500 mg  corre-
ponding to 8 × 109 CFU of S. cerevisiae CNCM I-3856 was chosen.
his choice was based both on the known classical range of active
robiotic concentrations used in human clinical trials [11] and on
reclinical studies performed in rats showing that escalating doses
f this strain of yeast gave a linear analgesic dose-dependent effect
eginning at 105 CFU/d and reaching a plateau at 109 CFU/d [13].
After  4 weeks of treatment, the improvement of abdomi-
al pain/discomfort, deﬁned by a reduction in the abdominal
ain/discomfort score of 1 for at least 50% of the time, was  signif-
cantly higher in patients receiving S. cerevisiae CNCM I-3856 than
n the placebo group. This decrease in score activity in the activend Liver Disease 47 (2015) 119–124 123
group  represented a mean 37.5% reduction in the initial visual ana-
logue Likert scale rating of abdominal pain severity. During the
ﬁrst month of treatment, changes in the intensity of abdominal
pain/discomfort were similar in the groups of patients receiving the
treatment or the placebo, suggesting a potential delayed action of
S. cerevisiae to induce analgesia. This hypothesis is consistent with
previous ﬁndings obtained in rodents where the analgesic effect of
S. cerevisiae CNCM I-3856 appeared two  weeks after the beginning
of treatment [13]. This delayed action of S. cerevisiae may  explain,
at least in part, why the difference for the weekly scores evaluating
abdominal pain/discomfort during the 8-week period of treatment
was in favour of S. cerevisiae CNCM I-3856 therapy but without sig-
niﬁcant intergroup differences. The present clinical trial included a
3-week follow-up to determine treatment durability [19]. The dif-
ferent proﬁles of abdominal pain/discomfort scores in the placebo
and product groups during this period showed a signiﬁcant increase
of abdominal pain only in the product group at one week after the
last administration of S. cerevisiae CNCM I-3856. These data sug-
gest that, similarly to our preclinical study performed in rats [13],
the analgesic effect induced by oral administration of S. cerevisiae
CNCM I-3856 in IBS patients is transitory and limited to the time of
product administration.
Evidence from the review literature outlines that a signiﬁcant
proportion of IBS patients receiving a placebo respond to therapy
[21,22]. The magnitude of this placebo response rate in random-
ized clinical trials conducted in Europe may vary from 0% to 91.7%,
with a mean value of 43% [21]. In our study, the improvement of
abdominal pain in 47% of IBS subjects receiving a placebo is con-
sistent with the placebo response rate observed in most European
single-centre trials [21,23]. Nevertheless, the statistically signiﬁ-
cant reduction in the abdominal pain/discomfort score of 1 au for
at least 50% of the time in 63% versus 47% of subjects receiving the
product versus placebo raises the question of the clinical beneﬁt in
IBS patients derived from taking S. cerevisiae CNCM I-3856. There is
no consensus deﬁning what would constitute a clinically meaning-
ful improvement for IBS patients [11]. Some studies accept a 10%
reduction in a visual analogue scale rating of symptom severity [24]
or a 1-point reduction on a 7-step ordinal scale [25]. In the present
clinical trial, the decrease of 1.2 points on the 7-point Likert scale
measuring abdominal pain, and the 63% improvement of abdominal
pain for at least 50% of the time in subjects receiving the product,
suggest that this improvement could be clinically relevant with a
therapeutic beneﬁt from taking S. cerevisiae CNCM I-3856 versus
placebo.
Probiotics are living bacteria, viruses, parasites, or yeasts
having demonstrated functional or health beneﬁts for the con-
sumer. Probiotic administration is considered as a promising, safe,
and acceptable strategy in IBS [11]. Most studies evaluating the
effects of probiotics in IBS patients have been performed with
bacterial strains of lactobacilli and/or biﬁdobacteria [11]. Despite
the numerous advantages offered by yeast compared to bacteria,
including antibiotic and phage resistances, as well as higher natural
robustness against gastric acid and bile salts, and stronger capacity
to regulate the innate immune response [26], only two  clinical
trials assessed the effect of yeast in patients with IBS [27,28]. These
two randomized double-blind placebo-controlled clinical trials
showed no superiority of Saccharomyces boulardii, given daily
at 500 mg  during 1 month, compared to placebo for individual
symptoms and, particularly, abdominal pain/discomfort in patients
with IBS-D and/or IBS-M. Given the signiﬁcant differences in the
enrolled populations in our study, i.e. mainly IBS-C rather than
IBS-D patients, and the longer duration of treatment (2 vs 1 month),
the comparison between these previously published studies and
our present clinical trial remains difﬁcult. The different biochem-
ical characteristics and the genomic and functional properties,
particularly regarding their ability to activate the peroxisome
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roliferator-activated receptor alpha versus gamma  [13,15,29],
etween S. cerevisiae and boulardii may  also explain the different
ctivity of these yeasts on the regulation of abdominal pain.
In  conclusion, S. cerevisiae CNCM I-3856 at 500 mg/day, conve-
iently delivered once daily by one capsule, is well tolerated and
educes abdominal pain/discomfort scores without altering stool
requency and consistency. Further clinical studies are warranted
o conﬁrm that S. cerevisiae could be a new promising candidate to
mprove abdominal pain/digestive discomfort in subjects with IBS.
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